Printer Friendly

Stemedica: patent for use of multiple stem cell lines to treat ischemic stroke.

SAN DIEGO, Calif., October 1, 2014 -- Stemedica Cell Technologies, Inc., was issued a U.S. patent (No. 8,790,638, "Composition of Stem Cells and Stem Cell Factors for Their Use and Manufacture") covering a method for treating patients with ischemic stroke.

The treatment includes intrathecal administration of hypoxically grown neural stem cells and intravenous administration of hypoxically grown mesenchymal stem cells.

"The issuance of this patent by the USPTO confirms a novel approach in the world of stem cell medicine: the simultaneous use of multiple stem cell lines to treat diseases," said Stemedica President Nikolai Tanko vich.

The approach targets various damaged tissues syncrgistically and uses different repair mechanisms that include, but are not limited to, treating a brain stroke from both sides of the blood-brain barrier.

Intravenous administration of Stemedica's ischemia-tolerant mesenchymal stem cells (itMSCs) is expected to help to release hundreds of repair proteins --the paracrine function of stem cells--to restore and build new vascularization and to improve the blood supply in tissues affected by stroke.

Via intrathecal administration, Stemedica's ischemia-tolerant neural stem cells (itNSCs) will migrate to and replace damaged neurons, engraft into the brain's neural network and produce neuromediators and electrical pulses to reconnect the damaged neural network and improve functionality of areas affected by the stroke.

Licensed by California's Food and Drug Branch, Stemedica produces multiple adult, allogeneic stem cell lines grown under low-oxygen conditions (US Patent 8,420,394 entitled "Culturing Ectodermal Cells Under Reduced Oxygen Tension"), which is their natural environment in the body.

Contact: http://www.stemedica.com

COPYRIGHT 2014 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Patents
Publication:Stem Cell Business News
Geographic Code:1U9CA
Date:Oct 6, 2014
Words:257
Previous Article:Researchers receive $5.8 m federal grant to build 3D liver model.
Next Article:Cell isolation/separation market to be worth $5.1 b by 2019.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |